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Abstract
The first Buenos Aires Breast Cancer Symposium (BA-BCS) was held in a virtual format, between the  17th and the  21st of 
May 2021. The main goal of the meeting was to facilitate the interaction among physicians and basic researchers from South 
America and with peers from the rest of the world. To embrace their different interests and concerns, the congress included 
not only talks on basic, translational and clinical research, but also round tables to discuss diagnostic methods, research 
financing and biobank management, as well as virtual poster sessions in which the youngest fellows presented their recent 
findings. This report provides a brief overview of the talks delivered during the meeting, which addressed a wide variety 
of vital issues for breast cancer research mostly focused on the accurate diagnosis, prevention and treatment of this illness. 
The presentations included a wide spectrum of themes including hormone receptors and the relevance of their mutations, 
immunotherapy, cancer stem cells, mouse models, environmental hazards, genetics and epigenetics, local and systemic 
therapies, liquid biopsies, the metastatic cascade, therapy resistance and dormancy, among others.
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BCSC  Breast cancer stem cell
ER  Estrogen receptor
MIND  Mammary intraductal model
PDX  Patient-derived xenograft
PR  Progesterone receptor
SERM  Selective ER modulator
TNBC  Triple-negative breast cancer
The first Buenos Aires Breast Cancer Symposium was 
planned to be held on May 2020 at the Usina de Arte, a 
beautiful, huge historical building in the traditional La Boca 
district in Buenos Aires, capital city of Argentina. The main 
goal of the meeting was to expose young Latin American 
oncologists and investigators to the state of the art in breast 
cancer research and treatment. In the last years, the pos-
sibility of travelling abroad to participate in meetings has 
been almost prohibitive for local scientists and fellows, even 
before the pandemic. So we thought, if our scientists can-
not travel abroad, we have to take the international research 
community to Argentina, and that was the leitmotif of our 
project. But, between February and March 2020 the COVID-
19 pandemic spread around the world. In April we were opti-
mistic enough to postpone our meeting to October. Almost 
all speakers agreed on the new date, but of course we had 
to cancel once again. By November, we decided that we 
had to move to a virtual format. Once more, we wrote to all 
our original speakers and most of them accepted this new 
format.
During the virtual meeting we enjoyed 2 lectures, 27 
talks from invited speakers in 13 thematic mini-symposia, 
3 round tables and 81 posters, from which 11, all unpub-
lished when submitted, were selected by the Scientific Com-
mittee integrated by Omar Coso and Albana Gattelli from 
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IFIBYNE-UBA-CONICET, Buenos Aires, Argentina; Maria 
Roque (IHEM-CONICET, University of Cuyo, Mendoza, 
Argentina), Gaston Soria (CIBICI-CONICET, UNC, Cór-
doba, Argentina), Alfredo Molinolo and J. Silvio Gutkind 
(both from Moores Cancer Center, UCSD, San Diego, USA) 
to be discussed in the mini-symposia. The other accepted 
abstracts were presented in 4 sessions, each of which had 
between 85 to 110 attendees from different institutions from 
Argentina and other countries including Chile, Portugal, 
USA and UK. They were one of the meeting highlights, in 
which PhD students and postdoctoral fellows presented their 
unpublished results to the general audience in 4 min talks, 
with the possibility to continue the discussions with smaller 
groups in “private” google-meet “rooms” assigned to each 
poster.
In the opening conference, “Advances in Estrogen 
Receptor (ER) Targeted Approaches to Breast Cancer”, Dr. 
Geoffrey Greene (University of Chicago, Chicago, USA) 
took us on a journey of his pioneering discoveries, starting 
with the purification of the ER protein, the development of 
the first antibodies against ERα [1], the cloning of the ER 
gene [2], and the use of x-ray crystallography to understand 
how agonists and antagonists work [3]. He then moved on 
to his recent and novel discoveries of ESR1 mutations in 
metastatic breast cancers [4] and the use of new selective 
estrogen receptor modulators (SERMs) to target them. He 
also showed data from the mammary intraductal model 
(MIND), a variant of the patient-derived xenograft (PDX) 
animal model that has led to new clinical trials of lasofox-
ifene [5]. In addition, he is currently studying the potential 
protective benefit of a recently approved hormone replace-
ment therapy that combines an estrogen with a SERM. In 
summary, Dr. Greene showed not only that he has played a 
fundamental role in pivotal discoveries, but that he is still 
carrying out cutting edge research in the field.
The first minisymposium was focused on tumor heteroge-
neity and breast cancer therapy. Our invited speakers were 
Dr. Mohamed Bentites-Alj (University of Basel, Basel, Swit-
zerland), Dr. Jorge Reis Filho (Memorial Sloan Kettering 
Cancer Center, New York City, USA) and Dr. Catalina Lodil-
linsky, a young scientist working at Ángel H. Roffo Institute, 
Buenos Aires, Argentina, whose abstract was selected by the 
scientific committee. Dr. Bentires-Alj gave a very interest-
ing presentation showing the effect of the oxidoreductase 
ERO1A, which enhances HIF1α-VEGFA-mediated angio-
genesis and metastatic colonization [6]. He also showed 
that the increase in stress hormones during breast cancer 
progression resulted in the activation of the glucocorticoid 
receptor, increased lung metastases and reduced overall sur-
vival in preclinical models [7]. Next, Dr. Reis Filho clearly 
showed how triple negative breast cancer (TNBC) is actually 
a diverse group of diseases. He emphasized that a subset 
of rare low-grade TNBCs, such as secretory carcinomas, 
adenoid cystic carcinomas or adenomyoepitheliomas, harbor 
recurrent genetic alterations and lack TP53 mutations. The 
correlations between histological features in this subset of 
tumors, and their genomic alterations, open the door to tailor 
the treatment decisions for patients with TNBC according to 
the histological type [8, 9]. Finally, Dr. Lodillinsky referred 
to the kinase NME1 as a potent inhibitor of breast cancer 
progression and her research on the molecular mechanisms 
involved in its activity [10].
In the second session, Dr. Carol Lange, from University 
of Minnesota, Minneapolis, USA, highlighted the impor-
tance of progesterone receptor (PR) and glucocorticoid 
receptor phosphorylation in ligand-independent transcrip-
tional regulation of target genes required for breast cancer 
stem cell expansion, which may open the way to new treat-
ments [11, 12]. The next three presentations addressed the 
impact of modulating the tumor microenvironment in breast 
cancer progression. Dr. Jennifer Richer from University of 
Colorado, Aurora, USA, showed that targeting enzymes 
involved in tryptophan catabolism may reduce tumor pro-
gression by enhancing the anti-tumor immune response. She 
also emphasized the similarities between the mechanisms 
of immune suppression during pregnancy that ensure fetal 
tolerance and the immune suppressive mechanisms utilized 
by breast cancer. The hope is that further understanding of 
the hormonal regulation and reversible nature of the former 
can lead to ways to control the process during cancer [13]. 
Dr. Mariana Salatino (IBYME-CONICET, Buenos Aires, 
Argentina) focused on a new role for the antiprogestin mife-
pristone that reduced tumor growth and induced immuno-
genic cell death in a luminal mouse breast cancer model 
showing higher levels of isoform A than isoform B of PR 
[14]. Finally, the post-doctoral fellow Dr. Andrés Marcos 
Castellaro, from Dr. Germán Gil´s lab at National University 
of Córdoba, Córdoba, Argentina, provided further evidence, 
based on their previous studies [15], on how conditioned 
macrophages may induce tumor growth and endocrine resist-
ance through ER hyperphosphorylation and activation of the 
NF-κB pathway.
Breast Cancer Stem Cells (BCSC) and the de-differentiated 
phenotype were the topics of the following session, which 
included 3 speakers from European laboratories plus a short 
talk by a local PhD student. First, Dr. Jochen Maurer from 
University Hospital RWTH, Aachen, Germany, described his 
method to isolate, characterize, and propagate BCSC from 
triple-negative tumors after chemotherapy, and how it can 
be used as a tool to screen and test novel therapeutic agents 
[16]. Then Dr. Paolo Ceppi (University of Southern Denmark, 
Odense, Denmark) explained the relevance of metabolic path-
ways associated to the epithelial-to-mesenchymal transition 
and the stem cell-like phenotype [17]. Dr. Robert Clarke, 
from University of Manchester, UK, referred to the crucial 
role of bone marrow-derived cytokines for stimulating breast 
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cancer cell colonization in the bone. The data obtained by 
his group revealed that IL1β induces intracellular NFκB and 
CREB signaling in breast cancer cells, which lead to Wnt 
ligand secretion, autocrine Wnt signaling activation and CSC 
colony formation. Therefore, inhibiting this pathway could be 
an important strategy to prevent bone metastasis formation 
[18]. Finally, Martín García Solá from Dr. Kordon´s Labora-
tory (IFIBYNE-UBA-CONICET, Buenos Aires, Argentina) 
showed that bio-informatic integration of multiple scRNA-seq 
data-sets provides new insights into mammary gland develop-
ment [19].
The contribution of mouse models to new breakthrough 
discoveries for breast cancer prevention and treatment was 
the theme of Session 4. The first talk by Dr. Joseph Jerry 
from University of Massachusetts, Amherst, USA, was 
focused on the identification of mechanisms by which expo-
sure to endogenous hormones and environmental chemicals 
may impact on inherited breast cancer risk. To this end, Dr. 
Jerry mapped a locus in mouse chromosome 7 that includes 
a genetic modifier, which may regulate repair of estrogen-
induced DNA damage and would be responsible for the vari-
able mammary tumor risk in different mouse strains [20]. 
Next, Dr. Fariba Behbod (University of Kansas, Kansas City, 
USA) focused her talk on the MIND model that allows the 
in vivo analysis of ductal carcinoma in situ (DCIS) progres-
sion. She showed the relevance of the BCL9-STAT3 path-
way to DCIS invasive progression [21] and discussed efforts 
to “humanize” the MIND model to include the study of the 
immune system during DCIS evolution. Dr. William Muller, 
from Rosalind and Morris Goodman Cancer Center, Mon-
treal, Canada, showed that upon ablation of the canonical 
mTORC1 activator (Rheb1) in multiple transgenic mouse 
models, mammary tumors display mTOR gene mutations 
that allow constitutive activation of the kinase, indicating 
that mTORC1 activation is required for mammary tumor 
initiation [22]. Finally, Dr. Diego Grinman, a postdoc-
toral fellow at Dr. Wysolmerski’s laboratory (Yale School 
of Medicine, New Haven, USA) showed his recent results 
indicating that mammary tumor expression of parathyroid 
hormone-related protein (PTHrP) contributes to cancer pro-
gression and causes anorexia, possibly, through a calcium 
dependent mechanism.
The sixth session focused on the relevance of genetic and 
epigenetic alterations in breast cancer progression and their 
relationship with environmental hazards. Dr. Adrian Lee 
from University of Pittsburgh, USA, described the state-of-
the-art techniques for functional genomics characterization 
of breast cancer disease, highlighting the heterogeneity and 
diversity between primary breast carcinomas, local recur-
rent tumors, and the metastatic ones at genomics and tran-
scriptomics levels. Evolution of changes in progression to 
metastasis is now well described and highlights not only 
mechanisms of drug resistance but also new therapeutic 
targets [23–25]. Next talk, by Dr. Sophie Lelièvre (Institut de 
Cancérologie de l'Ouest, Pays de la Loire, France) was cen-
tered on environmental challenges and cancer risk build-up. 
She presented an interesting risk-on-chip model to analyze 
the additive effects of microenvironmental stressors, such 
as increased reactive oxygen species and matrix stiffness, 
on the epigenome of the breast epithelium. Her collabora-
tive results showed how pathways linked to oxidative stress 
synergize with the pesticide Glyphosate that influences the 
activity of TET demethylating enzymes to trigger tumor 
onset. She insisted on the importance of combining cell 
culture-based risk models and clinical data to help identify 
epigenetically controlled noncoding RNAs that may serve 
the evaluation of breast cancer risk [26–28]. Dr. Guenter 
Vollmer, from Technische Universität Dresden, Germany, 
showed that natural botanical extracts obtained from hops or 
honeybush, for example, may represent promising tools for 
a preventive strategy for hormone-dependent breast cancer. 
This is due to the negative impact on the activity of ERα in 
the breast, following the parallel activation of ERβ [29] or 
the aryl hydrocarbon receptor pathways by these extracts 
[30, 31]. Selected from poster abstracts, Santiago Madera´s 
talk referred to the continuity of pioneering discoveries by 
Dr. P. V. Elizalde´s group (IBYME-CONICET, Buenos 
Aires, Argentina) on the role of nuclear ErbB-2 in ErbB-
2-positive breast cancer [32–34]. Using transcriptomic and 
preclinical approaches he provided evidence indicating that 
nuclear ErbB-2 can be considered a therapeutic target in 
trastuzumab-resistant breast cancer.
The topics of mechano-signaling and the role of extracel-
lular matrix stiffness by Dr. Valerie Weaver (University of 
California, San Francisco, USA.), the intricate functional 
mechanism acting at the tumor microenvironment of metas-
tasis by Dr. John Condeelis (Albert Einstein Cancer Center, 
Bronx, USA) and the importance of disseminated cancer 
cell dormancy regulation by Dr. Julio Aguirre Ghiso (Icahn 
School of Medicine at Mount Sinai, New York City, USA) 
were addressed in Session 7. Throughout the presentations 
we learned about the key role that the interaction between 
BCSC and the microenvironment plays in the regulation of 
invasion and dormancy. Moreover, we saw how translational 
research approaches combining cutting edge technology, 
molecular biology and clinical research have allowed to 
move forward and advance to the point where several clini-
cal trials are in progress, or about to start. This highlights the 
fact that, most likely, these lines of research might represent 
new points for therapeutic intervention to develop treatments 
for metastatic cancer in the near future [35–38]. In addi-
tion, we had two excellent talks also related to the metastatic 
process, selected from the posters, describing ongoing lines 
of research involving the use of the hemostatic compound 
desmopressin as a repurposed drug for TNBC manage-
ment by the young investigator Dr. Juan Garona (National 
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University of Quilmes, Bernal, Argentina) and the role of 
hypoxia in resistance to HER2-targeted antibody thera-
pies by the PhD student Virginia Wolos from Dr. Gabriel 
Fiszman´s lab at Ángel H. Roffo Institute of Oncology, Uni-
versity of Buenos Aires, Argentina.
In Session 9, Dr. Steffi Oesterreich, from University of 
Pittsburgh, USA, showed current efforts to target mutant ER 
in breast cancer. She highlighted the different ER mutations 
that are present mainly in metastatic sites, but are absent in 
the primary tumor, and that may be studied in liquid biop-
sies. The mutations, including ESR1 hotspot point mutations 
at Y537S and D538G [39–44] and ESR1 fusion genes [25, 
45, 46] cause ligand independent activation of ER, resulting 
in endocrine resistant metastatic disease. In turn, Dr. Todd 
Miller (Dartmouth College, Lebanon, USA) focused on dor-
mant ER + cells that start to grow after prolonged estrogen 
deprivation and show changes in metabolism towards fatty 
acid oxidation, opening the possibility of using this pathway 
to target dormant breast cancer cells [47].
Session 10 focused on the efforts to unveil mecha-
nisms associated to novel targets that are important for the 
advancement of precision medicine. Dr. Violeta Serra from 
Vall d’Hebron Institut d’Oncologia (VHIO), Barcelona, 
Spain, reviewed the use of PARP inhibitors in BRCA1/2 
mutated tumors and pointed out the relevance of using pre-
dictive biomarkers that correlate with PARPi response [48]. 
Dr. Santiago Bella (Sanatorio Allende and Clínica Univer-
sitaria Reina Fabiola, Córdoba, Argentina) focused on the 
current availability and use of CDK inhibitors for advanced 
breast cancer in South America. Dr. Dejan Juric (Massachu-
setts General Hospital, Boston, USA) conducted a journey 
on the use of PI3K inhibitors in clinical trials. He pointed 
out the importance of detecting PIK3CA mutations not only 
in solid tissue, but also in circulating DNA, and highlighted 
the relevance of combining endocrine therapies with CDK 
and PI3K inhibitors at early stages to avoid cross resistance 
[49]. Next, we had two short talks selected from posters. The 
PhD student Andrés Elia reported a new trial conducted by 
Dr. C. Lanari (IBYME-CONICET, Buenos Aires, Argen-
tina) using the antiprogestin mifepristone in selected breast 
carcinomas with higher levels of isoform A than isoform B 
of PR. Finally, Dr. Fabiana Rossi, from Dr. M. Rossi Lab, 
at Austral University, Pilar, Argentina, showed promising 
pre-clinical data on the use of ubiquitin regulators as novel 
therapeutic targets [50].
On the last day of the meeting, in Session 12, Dr. Cath-
erine Park (University of California, San Francisco, USA) 
talked about how local ablative treatment of metastasis could 
improve outcomes in patients with limited metastatic dis-
ease. Particularly, she made a special reference to clinical tri-
als that test the efficacy of stereotactic ablative radiotherapy 
for the comprehensive treatment of oligometastatic cancers, 
as the SABR-COMET study [51]. In her talk, Dr. Victoria 
Costanzo from Alexander Fleming Institute, Buenos Aires, 
Argentina, indicated therapeutic approaches presently being 
applied in Argentina for HER2 + patients. She emphasized 
that many new treatments have emerged in the last 2 years 
for the advanced disease. She highlighted that the challenge 
is how to adapt them to the treatment of the early disease to 
cure more patients. Then, Dr. Florencia Perazzo (CEMIC, 
Buenos Aires, Argentina) proposed that there is enough 
data to establish a proof of principle for immunotherapy for 
both early and advanced TNBC. However, she pointed out 
that new combination regimens and more refined biomark-
ers should be established to improve the response and to 
better identify the patients that most likely would benefit 
from immunotherapy [52]. Matthew Winder from CRUK 
Beatson Institute, UK, was selected to present his abstract 
in this session. He showed evidence of a critical pro-survival 
role for MCL-1, a BCL-2 family protein, in TNBC [53]. 
The results indicate that targeting this protein has an impact 
on tumor progression and cancer stem-cell like behavior in 
breast cancer.
In the last minisymposium, Dr. Pedram Razavi, from 
Memorial Sloan Kettering Cancer Center, New York, USA, 
indicated the relevance of serial liquid biopsies for detec-
tion of minimal residual disease, monitoring treatment and 
following clonal evolution of breast tumors [54, 55]. He 
also referred to the strengths and weak points of analyzing 
circulating tumor DNA [56]. Next, Dr. Osvaldo Podhajcer 
from Leloir institute, Buenos Aires, Argentina, referred to 
the Breast Cancer Study initiative performed by the US-
Latin America Cancer Research Network. More than 1000 
tumors were characterized by gene-expression using cDNA 
microarrays and immunohistochemistry. Current studies, 
still unpublished, are presently carried on to analyze driven 
molecular pathways in the attempt to determine differences 
possibly associated to ancestry. Selected from the posters, 
the PhD student at IBYME-CONICET, Gabriela Pattacini 
referred to the establishment of patient derived xenograft 
(PDX) breast cancer bank in Buenos Aires, to test the effi-
cacy of existing and novel drugs that would lead to faster 
development of new therapeutic approaches.
In the Closing conference, Dr. Charles Perou (UNC 
Lineberger Comprehensive Cancer Center, Chapel Hill, 
USA) started his lecture “Quantitative Medicine for Breast 
Cancer Patients” talking about the seminal paper that 
described for the first time the molecular portraits of breast 
cancer, highlighting the impact of that study on the under-
standing of breast cancer biology as well as the improve-
ment of therapeutic decisions [57]. Then, he referred to 
the relevance of the “PAM50 ROR Score”, which allows 
to accurately distinguish between luminal A and luminal B 
tumors. This analysis, together with tumor size, permits to 
quantitatively predict recurrence, and thus facilitate deci-
sion making on the appropriate length of endocrine therapy 
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treatments [58]. Towards the end of his talk, Dr. Perou 
showed data underscoring the relevance of analyzing the 
immune anti-tumor activity as well as T-cell and B-cell sig-
natures [59] to predict treatment response of triple negative 
and HER2 + breast cancers [60]. This suggests that com-
bined tumor and microenvironment molecular profiles may 
provide new predictor markers for prospective use in patients 
with different tumor subtypes.
Besides these extraordinary sessions our symposium 
also included three round tables integrated by South 
American investigators that discussed issues that concern 
the local community of breast cancer researchers and phy-
sicians. In the first one, focused on Genomics Platforms 
Dr. Ernesto Korbenfeld from Hospital Británico, Buenos 
Aires, presented the Oncotype DX platform, showing data 
indicating that some postmenopausal women with ER + /
PR + /HER2- node positive breast cancer may safely avoid 
adjuvant chemotherapy, while premenopausal women on 
the same condition may still likely benefit from it. Next, 
Dr. Fernando Petracci (Alexander Fleming Institute, Bue-
nos Aires) showed the clinical utility of MammaPrint and 
BluePrint for determining prognosis and guiding decision-
making with respect to the administration of adjuvant 
chemotherapy in patients with newly diagnosed invasive 
breast cancer. The following round table on Bioreposito-
ries and Sample Management included five speakers: Dr. 
Andrea Bosaleh (Hospital Juan P. Garrahan, Buenos Aires, 
Argentina), Dr. Liliana Virginia Siede (UBA-UMSA, 
Buenos Aires, Argentina), Dr. Alfredo Molinolo (Moores 
Cancer Center, UCSD, San Diego, USA), Dr. Gonzalo 
Ardao (Army Central Hospital (HCFFAA), Montevideo, 
Uruguay) and Dr. Ana Palmero (Public Health Ministry, 
Argentina), all with expertise in tissue banking and pathol-
ogy. The talks and discussions were focused on regulatory 
and general management issues as well as on technical 
aspects of tissue processing. The participants agreed that 
there are still several matters to work on in the interaction 
between biobank administrators and institutional review 
boards in order to make breast cancer samples more avail-
able to the local scientific community. Finally, the roles 
of government and non-government agencies, as well as 
industry, and their interaction in supporting and promoting 
breast cancer research were discussed in the third round 
table. Dr. Andrea Llera (Leloir Institute, Buenos Aires) 
mentioned aspects not commonly addressed when basic 
researchers apply to clinical grants such as costs associ-
ated to subject (patient) transportation, follow up, nursing 
and care, etc. Dr. Daniel Gomez (National University of 
Quilmes, Bernal, Argentina) referred to the possibility of 
participating from Argentina in international consortiums 
in the context of The European Union calls. Dr. Rosana 
Felice (GlaxoSmithKline, Argentina) talked about the 
experience of GSK in collaborating with Argentinian 
governmental agencies for funding translational projects. 
Finally, Judith Najdorf (University of Buenos Aires and 
CONICET, Argentina) provided her vision as a social 
scientist dedicated to the analysis of funding and evalua-
tion of basic and translational scientific projects on health 
issues.
Conclusions and Perspectives
The first Buenos Aires Breast Cancer Symposium demon-
strated that building a constructive network among breast 
cancer basic researchers and clinicians from all around 
the world with a relevant participation of South American 
researchers, who are commonly underrepresented in most 
international meetings, is possible. We, the organizers, 
received excellent feedbacks from all participants, includ-
ing students who presented their results for the first time 
to an international audience, and experienced investigators 
working in the most important institutions around the world. 
Several new collaborative endeavors were initiated among 
participants even in the absence of face-to-face poster ses-
sions, coffee breaks, corridors, meals and drinks, which 
usually are the most productive moments for establishing 
collaborations in a scientific meeting.
We hope that this meeting represents a new step forward 
in the advancement of breast cancer research in Argentina, 
setting a milestone from which the scientific and the medical 
communities may further contribute towards improvements 
in the diagnosis, treatment and management of breast cancer. 
Many challenges lie ahead, many related to the fact that we 
are a developing country. We trust that the community, the 
authorities, and industry may find a way to work together 
with scientists to achieve this common goal. This was our 
first trial, and we hope to repeat and improve this experience 
in the near future.
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